- Home
- GTLS vs IBRX Comparison
GTLS vs IBRX Comparison
Compare GTLS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTLS | IBRX |
|---|---|---|
| Founded | 1859 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GTLS | IBRX |
|---|---|---|
| Price | $206.61 | $7.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $203.22 | $12.57 |
| AVG Volume (30 Days) | 2.1M | ★ 24.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $17.24 | $88.59 |
| Revenue Next Year | $6.26 | $131.15 |
| P/E Ratio | $240.25 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $104.60 | $1.83 |
| 52 Week High | $208.24 | $12.43 |
Technical Indicators
Market Signals| Indicator | GTLS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 48.47 |
| Support Level | $206.55 | $2.25 |
| Resistance Level | $207.59 | $8.28 |
| Average True Range (ATR) | 0.48 | 0.93 |
| MACD | -0.05 | -0.24 |
| Stochastic Oscillator | 24.40 | 39.00 |
Price Performance
Historical ComparisonAbout GTLS Chart Industries Inc.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.